Numab Therapeutics funding news – Numab Therapeutics has Secured $55 Million in Series C Round Funding

The financing was co-led by Cormorant Asset Management, Forbion via its Forbion Growth Opportunities Fund, HBM Healthcare Investment, and Novo Holdings, with participation from other existing investors BVF Partners L.P., Octagon Capital Advisors LP, RTW Investments, and funds and accounts managed by BlackRock.

Read also - VitVio funding news – London-based VitVio has Secured €1.8 Million in Pre-Seed Funding

Bihua Chen, Founder and CEO of Cormorant Asset Management said, "We believe that Numab's modular platform and engineering expertise in designing multi- specific antibodies with predictable stability, yield, and good CMC characteristics have significant advantages. We also believe multi-specific antibodies have the advantage of more efficient clinical trial design. We are excited to continue to support the team as they identify and pursue the best rational biological combinations for their platform".

David Urech, Ph.D., Founder and Chief Executive Officer of Numab Therapeutics said, "Throughout 2024, we made tremendous progress with our pipeline and business development efforts, including the acquisition of Numab's spin-out Yellow Jersey Therapeutics by Johnson & Johnson for $1.25 billion, We are delighted to start the year by strengthening our financial position with the support of this strong group of investors who share our vision and conviction in the strength of Numab's unique A-Cap™ and MATCHM technology platforms and our regional partnering strategy that allows us to de-risk development of our proprietary pipeline."

Proceeds from the financing will be used to accelerate and further advance Numab's pipeline of clinical and pre-clinical best-in-class and first-in-class multi-specific antibodies in inflammation and oncology.

About Numab Therapeutics

Numab Therapeutics is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Reproducible plug-and-play therapeutic design process using proprietary platforms λ-Cap™ and MATCH™ puts Numab in a unique position to overcome historical drug discovery barriers and build a pipeline of first-in-class and best-in-class medicines aimed to maximize patient benefits.